Current Liabilities
Short-Term Borrowings
Bristol-Myers Squibb Short-Term Borrowings decreased by 49.9% to $2.26B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 10.5%, from $2.05B to $2.26B. Over 5 years (FY 2020 to FY 2025), Short-Term Borrowings shows relatively stable performance with a -0.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalLower is better
VolatilityModerate
First reportedQ4 2014
Last reportedQ4 2025
How to read this metric
High levels may indicate a reliance on short-term credit markets for operational cash flow, which can increase liquidity risk.
Detailed definition
Short-term borrowings consist of debt obligations that are due within one year, excluding the current portion of long-te...
Peer comparison
Varies by industry; pharmaceutical firms often maintain access to short-term credit for operational flexibility.
Metric ID:
short_term_borrowingsHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.66B | $5.07B | $4.95B | $7.52B | $4.95B | $2.13B | $4.26B | $2.75B | $3.02B | $5.47B | $3.12B | $6.19B | $3.53B | $1.08B | $2.05B | $3.55B | $4.72B | $4.51B | $2.26B |
| QoQ Change | — | +90.8% | -2.3% | +52.0% | -34.2% | -57.0% | +100.0% | -35.5% | +9.7% | +81.0% | -42.9% | +98.5% | -43.0% | -69.5% | +89.8% | +73.7% | +32.7% | -4.4% | -49.9% |
| YoY Change | — | — | — | — | +86.6% | -57.9% | -13.8% | -63.4% | -39.0% | +156.4% | -26.9% | +124.9% | +16.9% | -80.3% | -34.4% | -42.6% | +33.5% | +318.3% | +10.5% |
Range$1.08B – $7.52B
CAGR-3.5%
Avg YoY Growth+25.9%
Median YoY Growth-13.8%
Current Streak2 quarters decline
Short-Term Borrowings at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's short-term borrowings?
- Bristol-Myers Squibb (BMY) reported short-term borrowings of $2.26B in Q4 2025.
- How has Bristol-Myers Squibb's short-term borrowings changed year-over-year?
- Bristol-Myers Squibb's short-term borrowings increased by 10.5% year-over-year, from $2.05B to $2.26B.
- What is the long-term trend for Bristol-Myers Squibb's short-term borrowings?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's short-term borrowings has grown at a -0.7% compound annual growth rate (CAGR), from $2.34B to $2.26B.
- What does short-term borrowings mean?
- Debt that must be repaid within the next twelve months.